Charles Jobson Purchases 15,397 Shares of Joint (NASDAQ:JYNT) Stock

The Joint Corp. (NASDAQ:JYNTGet Free Report) major shareholder Charles Jobson purchased 15,397 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $8.50 per share, for a total transaction of $130,874.50. Following the acquisition, the insider owned 1,645,294 shares of the company’s stock, valued at $13,984,999. The trade was a 0.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Joint Price Performance

Shares of NASDAQ JYNT traded up $0.24 during mid-day trading on Tuesday, hitting $8.92. The company’s stock had a trading volume of 51,131 shares, compared to its average volume of 57,714. The Joint Corp. has a one year low of $7.50 and a one year high of $13.47. The company’s fifty day simple moving average is $9.28 and its 200-day simple moving average is $9.31. The stock has a market cap of $132.64 million, a price-to-earnings ratio of -148.64 and a beta of 1.35.

Institutional Investors Weigh In On Joint

Several institutional investors have recently bought and sold shares of JYNT. Nisa Investment Advisors LLC raised its holdings in shares of Joint by 5,141.9% in the second quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company’s stock valued at $26,000 after purchasing an additional 2,211 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Joint by 104.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock worth $28,000 after purchasing an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Joint by 32.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after purchasing an additional 1,810 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Joint by 25.9% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after buying an additional 1,698 shares during the last quarter. Finally, Stoneridge Investment Partners LLC bought a new position in shares of Joint in the third quarter valued at $117,000. Institutional investors own 76.88% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on JYNT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Joint in a research note on Thursday, January 22nd. B. Riley Financial downgraded shares of Joint from a “buy” rating to a “hold” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Joint presently has an average rating of “Hold” and a consensus target price of $17.00.

View Our Latest Research Report on Joint

About Joint

(Get Free Report)

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.

Featured Articles

Insider Buying and Selling by Quarter for Joint (NASDAQ:JYNT)

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.